Unaltered prion protein expression in Alzheimer disease patients

Prion

Volumn 5, Issue 2, 2011, Pages 109-116

  Saijo, Eri ^a   Scheff, Stephen W ^a   Telling, Glenn C ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

Author keywords

Alzheimer disease; Alzheimer precursor protein; Oligomeric A ; Prion protein; PrP codon 129 polymorphism

Indexed keywords

AMYLOID BETA PROTEIN; METHIONINE; PRION PROTEIN; VALINE; AMYLOID PRECURSOR PROTEIN;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITION; DNA POLYMORPHISM; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; MALE; MILD COGNITIVE IMPAIRMENT; PATHOGENESIS; PROTEIN EXPRESSION; TEMPORAL CORTEX; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PHYSIOLOGY; PRION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; FEMALE; HUMANS; MALE; POLYMORPHISM, GENETIC; PRIONS; PRPC PROTEINS;

EID: 79959469273     PISSN: 19336896     EISSN: 1933690X     Source Type: Journal    
DOI: 10.4161/pri.5.2.16355     Document Type: Article

References (34)

1. Prusiner SB. Prions. Proc Natl Acad Sci USA 1998; 95:13363-83.
2. Schmitt-Ulms G, Hansen K, Liu J, Cowdrey C, Yang J, DeArmond SJ, et al. Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nat Biotechnol 2004; 22:724-31. (Pubitemid 38702829)
3. Chen SG, Teplow DB, Parchi P, Teller JK, Gambetti P, Autilio-Gambetti L. Truncated forms of the human prion protein in normal brain and in prion diseases. J Biol Chem 1995; 270:19173-80.
4. Yadavalli R, Guttmann RP, Seward T, Centers AP, Williamson RA, Telling GC. Calpain-dependent endoproteolytic cleavage of PrPSc modulates scrapie prion propagation. J Biol Chem 2004; 279:21948-56. (Pubitemid 38679385)
5. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature 2009; 457:1128-32.
6. Martins RN, Harper CG, Stokes GB, Masters CL. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 1986; 46:1042-5. (Pubitemid 16010948)
7. Brazier MW, Lewis V, Ciccotosto GD, Klug GM, Lawson VA, Cappai R, et al. Correlative studies support lipid peroxidation is linked to PrP(res) propagation as an early primary pathogenic event in prion disease. Brain Res Bull 2006; 68:346-54. (Pubitemid 41827717)
8. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, et al. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci USA 2009; 106:12926-31.
9. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral beta-amyloidogenesis is governed by agent and host. Science 2006; 313:1781-4. (Pubitemid 44454153)
10. Eisele YS, Obermuller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, et al. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330:980-2.
11. Baier M, Apelt J, Riemer C, Gultner S, Schwarz A, Bamme T, et al. Prion infection of mice transgenic for human APPSwe: increased accumulation of cortical formic acid extractable Abeta(1-42) and rapid scrapie disease development. Int J Dev Neurosci 2008; 26:821-4.
12. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB, Manson JC, et al. Cellular prion protein regulates beta-secretase cleavage of the Alzheimer's amyloid precursor protein. Proc Natl Acad Sci USA 2007; 104:11062-7. (Pubitemid 47175226)
13. Brundin P, Melki R, Kopito R. Prion-like transmission of protein aggregates in neurodegenerative diseases. Nat Rev Mol Cell Biol 2010; 11:301-7.
14. Frost B, Jacks RL, Diamond MI. Propagation of tau misfolding from the outside to the inside of a cell. J Biol Chem 2009; 284:12845-52.
15. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc Natl Acad Sci USA 2009; 106:13010-5.
16. Ren PH, Lauckner JE, Kachirskaia I, Heuser JE, Melki R, Kopito RR. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates. Nat Cell Biol 2009; 11:219-25.
17. Del Bo R, Scarlato M, Ghezzi S, Martinelli-Boneschi F, Fenoglio C, Galimberti G, et al. Is M129V of PRNP gene associated with Alzheimer's disease? A case-control study and a meta-analysis. Neurobiol Aging 2006; 27:7701-5.
18. Riemenschneider M, Klopp N, Xiang W, Wagenpfeil S, Vollmert C, Muller U, et al. Prion protein codon 129 polymorphism and risk of Alzheimer disease. Neurology 2004; 63:364-6. (Pubitemid 38971146)
19. Gimbel DA, Nygaard HB, Coffey EE, Gunther EC, Lauren J, Gimbel ZA, et al. Memory impairment in transgenic Alzheimer mice requires cellular prion protein. J Neurosci 2010; 30:6367-74.
20. Calella AM, Farinelli M, Nuvolone M, Mirante O, Moos R, Falsig J, et al. Prion protein and Abeta-related synaptic toxicity impairment. EMBO Mol Med 2010; 2:306-14.
21. Balducci C, Beeg M, Stravalaci M, Bastone A, Sclip A, Biasini E, et al. Synthetic amyloid-beta oligomers impair long-term memory independently of cellular prion protein. Proc Natl Acad Sci USA 107:2295-300.
22. Wadsworth JD, Asante EA, Desbruslais M, Linehan JM, Joiner S, Gowland I, et al. Human prion protein with valine 129 prevents expression of variant CJD phenotype. Science 2004; 306:1793-6.
23. Li X, Rowland LP, Mitsumoto H, Przedborski S, Bird TD, Schellenberg GD, et al. Prion protein codon 129 genotype prevalence is altered in primary progressive aphasia. Ann Neurol 2005; 58:858-64. (Pubitemid 41748288)
24. Dermaut B, Croes EA, Rademakers R, Van den Broeck M, Cruts M, Hofman A, et al. PRNP Val129 homozygosity increases risk for early-onset Alzheimer's disease. Ann Neurol 2003; 53:409-12. (Pubitemid 36258648)
25. Sc)-specific epitope defined by a monoclonal antibody. Nature 1997; 389:74-7.
26. Rubenstein R, Kascsak RJ, Papini M, Kascsak R, Carp RI, LaFauci G, et al. Immune surveillance and antigen conformation determines humoral immune response to the prion protein immunogen. J Neurovirol 1999; 5:401-13. (Pubitemid 29391121)
27. Lund C, Olsen CM, Tveit H, Tranulis MA. Characterization of the prion protein 3F4 epitope and its use as a molecular tag. J Neurosci Methods 2007; 165:183-90. (Pubitemid 47212461)
28. Zou WQ, Langeveld J, Xiao X, Chen S, McGeer PL, Yuan J, et al. PrP conformational transitions alter species preference of a PrP-specific antibody. J Biol Chem 2010; 285:13874-84.
29. Velayos JL, Irujo A, Cuadrado-Tejedor M, Paternain B, Moleres FJ, Ferrer V. The cellular prion protein and its role in Alzheimer disease. Prion 2009; 3:110-7.
30. Voigtlander T, Kloppel S, Birner P, Jarius C, Flicker H, Verghese-Nikolakaki S, et al. Marked increase of neuronal prion protein immunoreactivity in Alzheimers disease and human prion diseases. Acta Neuropathol 2001; 101:417-23. (Pubitemid 32600131)
31. Davis DG, Schmitt FA, Wekstein DR, Markesbery WR. Alzheimer neuropathologic alterations in aged cognitively normal subjects. J Neuropathol Exp Neurol 1999; 58:376-88. (Pubitemid 29187900)
32. Schmitt FA, Davis DG, Wekstein DR, Smith CD, Ashford JW, Markesbery WR. "Preclinical" AD revisited: neuropathology of cognitively normal older adults. Neurology 2000; 55:370-6.
33. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med 2004; 256:183-94. (Pubitemid 39222988)
34. Kurt TD, Telling GC, Zabel MD, Hoover EA. Transspecies amplification of PrP(CWD) and correlation with rigid loop 170N. Virology 2009; 387:235-43.